{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:21:58Z","timestamp":1789543318231,"version":"build-2803163510"},"reference-count":72,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Severe cutaneous adverse reactions (SCARs) [Stevens\u2013Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic syndrome (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed eruption (GBFE)] are severe drug reactions that often require hospitalization and could be fatal. BRAF and MEK inhibitors (BRAF\/MEKi) are a standard of care in patients with\n                    <jats:italic>BRAF<\/jats:italic>\n                    \u2010mutated metastatic melanomas. These agents are administered until disease progression or unacceptable toxicity occurs. This review has focus on BRAF\/MEKi\u2010induced SCARs. A systematic search of the following terms: \u2018vemurafenib\u2019, \u2018cobimetinib\u2019, \u2018dabrafenib\u2019, \u2018trametinib\u2019, \u2018encorafenib\u2019, \u2018binimetinib\u2019, \u2018Acute Generalized Exanthematous Pustulosis\u2019, \u2018Stevens Johnson syndrome\u2019, \u2018Toxic Epidermal Necrolysis\u2019, \u2018Generalized Bullous Fixed Eruption\u2019 \u2018Drug Hypersensitivity Syndrome\u2019, and \u2018DRESS\u2019 in simple combination (every drug with each disease) and all in combination, was performed on MEDLINE, EMBASE, Web of Knowledge and The Cochrane Library repositories, with no restriction on language, for original studies. One hundred sixty\u2010eight original articles were found, 26 (retrospective series, case reports and conference abstracts) were selected, and 21 were included in the qualitative synthesis. A total of 31 SCAR cases (23 DRESS and 8 SJS\/TEN \u2013 1 SJS and 7 TEN \u2013) were identified. Vemurafenib was the culprit drug in all but one case, which was dabrafenib\u2010induced. Mean time to SCAR onset from drug intake was 15.5 and 11.4\u00a0days, for SJS\/TEN and DRESS, respectively. For the DRESS cases, hepatic involvement occurred in 96% and renal alterations in 87% of patients. Overall, BRAF\/MEKi\u2010induced SCARs are rare. Among them, vemurafenib is the drug that requires more close monitoring for SCARs. Prior immunotherapy can favour SCARs. Vemurafenib DRESS is likely to occur within the first fifteen days of treatment accompanied by hepatic and renal involvement. Following vemurafenib\u2010induced SCAR resolution, switching to dabrafenib seems to be a safe alternative for these patients\u2019 treatment.\n                  <\/jats:p>","DOI":"10.1111\/jdv.16894","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T01:25:53Z","timestamp":1598491553000},"page":"607-614","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Systematic review of BRAF\/MEK inhibitors\u2010induced Severe Cutaneous Adverse Reactions (SCARs)"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-5360","authenticated-orcid":false,"given":"I.","family":"Torres\u2010Navarro","sequence":"first","affiliation":[{"name":"Dermatology Department Hospital Universitario y Polit\u00e9cnico la Fe Val\u00e8ncia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4073-145X","authenticated-orcid":false,"given":"B.","family":"de Unamuno\u2010Bustos","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital Universitario y Polit\u00e9cnico la Fe Val\u00e8ncia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-8192","authenticated-orcid":false,"given":"R.","family":"Botella\u2010Estrada","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital Universitario y Polit\u00e9cnico la Fe Val\u00e8ncia Spain"},{"name":"Department of Medicine Universitat de Val\u00e8ncia Val\u00e8ncia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1988.tb04923.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30378-6"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16365"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00825-2"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2013.10.054"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5278"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2015.03.008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14201"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000439272"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083138"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07704.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000472"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.02.033"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.08.003"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000487128"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.06.027"},{"key":"e_1_2_6_26_1","article-title":"DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem","volume":"2018","author":"Ros J","year":"2018","journal-title":"BMJ Case Rep"},{"key":"e_1_2_6_27_1","doi-asserted-by":"crossref","unstructured":"Riggioni V\u00edquezS Garc\u00eda MoralA Araujo S\u00e1nchezC Rib\u00f3 Gonz\u00e1lezP De La RocaPF Mu\u00f1oz CanoRet al.Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to vemurafenib. Abstracts TPS (abstract no1165).In: Allergy [Internet].2018. p.370\u2013702.","DOI":"10.26226\/morressier.5acc8ad3d462b8028d89b5ac"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.029"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14852"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000388"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","unstructured":"LuengoO SalaA LabradorM Munoz\u2010CouseloE CardonaV FarriolsAet al.Dabrafenib: a safe alternative in two patients with vemurafenib\u2010induced dress. Poster Session TPS (no1121). In: Allergy [Internet].2017. p.383\u2013757.","DOI":"10.1111\/all.13252"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13522"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14010"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14150"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0456"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13958"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-013-0308-6"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121950"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0045-5"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70413-8"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13751"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416670368"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12430"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000281"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2015.08.002"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-018-1953-x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3319"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0606"},{"key":"e_1_2_6_49_1","first-page":"817","article-title":"Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives Vol. 20, American Journal of Clinical Dermatology","volume":"20","author":"Testori AAE","year":"2019","journal-title":"ADIS"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.01.006"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12501"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.09.036"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1114329"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0092"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S163391"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13275"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.3.323"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14530"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.01.032"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2009.04.007"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.08.050"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.01.032"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12773"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283573437"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12796"},{"key":"e_1_2_6_68_1","unstructured":"EhmannLM HubingerL FrankJ SchulteKW HomeyB MellerS.Stevens\u2010Johnson\u2010Syndrom unter Vemurafenib. Poster No20. In: der DDG KOMPAKT. Hamburg: Journal der Deutschen Dermatologischen Gesellschaft;2014. p.11."},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13443"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0475-y"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13174"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12685"},{"key":"e_1_2_6_73_1","unstructured":"Bourneau\u2010MartinD VeyracG BernierC GaboriauL Ponte\u2010AstoulJ ParetNet al.Early Onset Vemurafenib\u2010Cobimetinib Induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: a Case Series. Poster No108. In: 17th ISoP Annual Meeting \u2018\u201cPharmacovigilance in the 21st Century.\u201d\u2019 Liverpool: Drug Saf;2017. p.981."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16894","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T18:33:39Z","timestamp":1693679619000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/jdv.16894"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16894","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"2020-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}